← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Research (597)Review article (228)Early Study (Phase 1 or 2) (43)Case report (177)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (39)

Filter

Publications and studies (1632)

• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Characterization of a human induced Pluripotent Stem (iPS) cell line (INCABRi002-A) derived from a primary myelofibrosis patient harboring the 5-bp insertion in CALR and the p.W146X mutation in TP53. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Protein-dysregulation in human and murine myeloproliferative neoplasms]. (2018/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Pacritinib in Patients With Myelofibrosis. (2018/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Pacritinib in Patients with Myelofibrosis-Reply. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. (2018/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Renal failure and progressive pancytopenia. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review]. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Potential Value of Cancer-Associated Fibroblasts in Hematological Malignancies--Review]. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? (2018/12/01) ♡
• Clinical diagnosis of adult patients with acute megakaryocytic leukemia. (2018/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Male with myelofibrosis and ulceronecrotic lesions. (2018/12/01) ♡
• EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS. (2018/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. (2018/11/30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. (2018/11/30) ♡
• Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. (2018/11/28) ♡
• Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. (2018/11/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. (2018/11/21) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. MPL-mutated essential thrombocythemia: a morphologic reappraisal. (2018/11/20) ♡
• Publisher Correction: Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. (2018/11/20) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. (2018/11/19) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Genetic predictors of response to specific drugs in primary myelofibrosis. (2018/11/19) ♡
• Acute variceal bleeding in patients with primary myelofibrosis successfully treated with endoscopic histoacryl injection. (2018/11/19) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Prefibrotic myelofibrosis: treatment algorithm 2018. (2018/11/07) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease. (2018/11/04) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. (2018/11/01) ♡
• Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study. (2018/11/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. (2018/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel treatments to tackle myelofibrosis. (2018/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver. (2018/11/01) ♡
• β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. (2018/11/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis. (2018/10/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Development of Serum Amyloid P as a Possible Therapeutic. (2018/10/16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. (2018/10/11) ♡
• Splenic mass in a case of CALR-mutated essential thrombocythemia. (2018/10/09) ♡
• Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance. (2018/10/02) ♡
• Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis. (2018/10/01) ♡
• Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. (2018/10/01) ♡
• Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. What is pre-fibrotic myelofibrosis and how should it be managed in 2018? (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Reversible myelofibrosis due to severe Vitamin D deficiency rickets. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. (2018/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. (2018/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study(⁎). (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. TAFRO Syndrome: A Case Report from Turkey and Review of the Literature. (2018/10/01) ♡
• Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs. (2018/10/01) ♡
• Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs. (2018/10/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib. (2018/09/21) ♡
• Oxidative and nitrosative stress in myeloproliferative neoplasms: the impact on the AKT / mTOR signaling pathway. (2018/09/01) ♡
• Esophageal Variceal Hemorrhage Secondary to Post-Polycythemic Myelofibrosis. (2018/09/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Syndromic congenital myelofibrosis associated with a loss-of-function variant in RBSN. (2018/08/09) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.